Greater Glasgow and Clyde Medicines

Latest Medicines Updates & News -2015

MUE 04: PPIs

Posted: Friday, December 18, 2015

Category - Medicines Update Extra

  Oral Proton Pump Inhibitors

  • Proton Pump Inhibitors (PPIs) are one of the most commonly prescribed classes of drug
  • PPIs are an effective treatment when used appropriately
  • PPIs should only be prescribed where there is a clear indication
  • PPIs are usually well tolerated
  • Recent evidence suggests that PPIs may have potentially serious adverse effects such as fractures, hypomagnesaemia, subacute cutaneous lupus erythematosus, pneumonia and Clostridium difficile infection

Naloxone take home doses

Posted: Monday, November 23, 2015

Category - Medicines Update Acute

Opioid drug users are at a high risk of a drug related death on discharge from hospital. Services have been developed to ensure those with a current or previous history of opiate misuse are given overdose awareness training and a naloxone suppl...

MUE 03: Management of Urinary Incontinence and Overactive Bladder

Posted: Monday, November 9, 2015

Category - Medicines Update Extra

  Management of Urinary Incontinence and Overactive Bladder

  • Lifestyle interventions and non-pharmacological strategies should be tried as first-line treatment.
  • If pharmacological therapy is indicated, antimuscarinics should be tried first line.
  • Immediate release (IR) oxybutynin, IR and modified release (MR) tolterodine and solifenacin are on the Preferred List of the Formulary.
  • IR oxybutynin and IR tolterodine are significantly less expensive than other preparations on the Formulary, however, they may have less tolerability.
  • MR tolterodine has similar efficacy and tolerability to solifenacin but is significantly less expensive, therefore, consider prescribing MR tolterodine prior to solifenacin.
  • Patients should be reviewed 4 weeks after starting each new therapy and after a dose change.
  • Patients on long term therapy should be reviewed annually or every 6 months if over 75 years.